Tresiba® and Ryzodeg® receive marketing authorisations in Europe
21 January 2013 | By Novo Nordisk
“We look forward to making Tresiba® and Ryzodeg® available to many people with diabetes in Europe”
List view / Grid view
News
Pfizer’s Bosutinib receives positive opinion
18 January 2013 | By Pfizer
“We are very pleased with this positive recommendation on bosutinib by the CHMP..."
Novartis receives positive CHMP opinion for Ilaris®
18 January 2013 | By Novartis
"Novartis welcomes the decision by the CHMP in support of the approval of Ilaris in the EU"
Jetrea(TM) receives positive CHMP opinion
18 January 2013 | By Novartis
Jetrea(TM) would become the first drug to treat sight-threatening vitreomacular traction and macular hole...
Hyglos extends its endotoxin detection portfolio and introduces EndoZyme® – enhanced recombinant Factor C (rFC) Assay
Hyglos has announced the commercial launch of EndoZyme®, a homogeneous fluorescence microplate assay using recombinant Factor C derived from horseshoe crab, for measuring endotoxin (Lipopolysaccharides, LPS) in pharmaceuticals, biologics and medical equipment.
Boehringer Ingelheim and the EFSD call for grant applications in diabetes research
17 January 2013 | By Boehringer Ingelheim
Submissions opened for diabetes research grant applications from across Europe...
Veridex and LabCorp agreement brings CellSearch CTC test to China
17 January 2013 | By Johnson & Johnson
Veridex LLC announced an agreement with LabCorp Clinical Trials...
Novartis makes progress in the fight to eliminate leprosy worldwide
17 January 2013 | By Novartis
"The challenges in delivering healthcare in developing countries are considerable..."
Bristol-Myers Squibb appoints Mike Burgess M.D., Ph.D. Senior Vice President, Discovery Medicine and Clinical Pharmacology
17 January 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb appoints Mike Burgess...
Boehringer Ingelheim enrols first patients in pivotal Phase III interferon-free hepatitis C trial programme
17 January 2013 | By Boehringer Ingelheim
"Diabetes affects more than 371m people..."
Vifor Pharma and China Medical System Holdings Limited sign distribution agreement
17 January 2013 | By Thomson Reuters
Vifor Pharma has entered into an exclusive distribution agreement with CMS...
Vestiq Pharmaceuticals, Inc. launches with agenda for rapid growth, acquires NDAs for ORAVIG® and Zuplenz® oral soluble film
16 January 2013 | By WHITECOAT Strategies, LLC
Vestiq announces its launch of products...
Lonza and BaroFold announce a technology evaluation agreement for PreEMT™
Lonza, a leader in biological development and BaroFold, Inc., an innovative protein technology developer, announced today a non-exclusive technology and license agreement whereby Lonza will evaluate BaroFold’s PreEMT™ high pressure refolding technology for use in biological development refolding processes.
European Commission approves PREZISTA® (darunavir) 800mg tablet once a day
16 January 2013 | By prnewswire.co.uk
The European Commission has approved a new PREZISTA® (darunavir) 800mg tablet...
Amgen announces top-line results of Phase 3 Aranesp® (darbepoetin alfa) RED-HF® trial
16 January 2013 | By Amgen
Amgen announced top-line results of the Phase 3 Aranesp® RED-HF® Trial...
